FCHS Launches $12M IPO of Convertible Preferred Stock, Warrants

Ticker: FCHS · Form: S-1/A · Filed: Sep 24, 2025 · CIK: 1416876

Sentiment: bearish

Topics: IPO, Convertible Preferred Stock, Warrants, Reverse Stock Split, Dilution Risk, Healthcare Solutions, Capital Raise

Related Tickers: FCHS

TL;DR

**FCHS's complex IPO with dilutive preferred stock and a massive reverse split is a high-risk gamble for investors, signaling potential future pain for common shareholders.**

AI Summary

First Choice Healthcare Solutions, Inc. (FCHS) is conducting an initial public offering of 2,400,000 shares of Series D Convertible Preferred Stock and accompanying Warrants to purchase an equal number of Series D Preferred Stock, aiming to raise $12,000,000 before underwriting discounts of $960,000 and expenses. The offering price is fixed at $5.00 per share and warrant, with an assumed conversion and exercise price of $5.00 per share. The company anticipates registering a total of 8,124,000 shares of Common Stock, including those issuable upon conversion of Preferred Stock and Warrants, and for dividend payments. A significant business change includes a proposed 1-for-2,000 reverse stock split for 32,958,288 outstanding common shares, effective after registration but before NYSE listing, which does not apply to shares from certain acquisitions. Post-offering, the three largest shareholders will collectively hold less than 1% of total voting power, and CEO Lance Friedman's Series A Super Voting Preferred Stock will be cancelled, preventing the company from being a 'controlled company.' A key risk is the anti-dilution provision in the Series D Preferred Stock, which could lower the conversion price in future offerings, leading to greater dilution and potentially insufficient authorized shares, thereby depressing common stock price and hindering future equity capital raises.

Why It Matters

This S-1/A filing is critical for investors as FCHS is undertaking a significant capital raise of $12 million through a complex offering of Series D Convertible Preferred Stock and Warrants, alongside a 1-for-2,000 reverse stock split. The anti-dilution provisions in the Series D Preferred Stock pose a substantial risk, potentially leading to significant future dilution for common shareholders if FCHS issues securities at a lower price, impacting the stock's value and the company's ability to raise capital. The cancellation of CEO Lance Friedman's super-voting shares and the reduced stake of major shareholders will alter the company's control structure, potentially affecting governance and strategic direction, making it a non-controlled company under NYSE American standards. Competitors in the healthcare solutions space will be watching to see if FCHS can successfully execute this offering and stabilize its capital structure.

Risk Assessment

Risk Level: high — The risk level is high due to the anti-dilution provisions in the Series D Convertible Preferred Stock, which mandate a lower conversion price if future offerings are priced below $5 per share, leading to greater dilution for common shareholders. The filing explicitly states, "As there is no floor price on the Conversion Price, we cannot determine the total number of shares issuable upon conversion," indicating unpredictable and potentially severe dilution. Additionally, the proposed 1-for-2,000 reverse stock split on 32,958,288 shares, while not directly dilutive, often precedes further share price declines and can signal underlying financial distress.

Analyst Insight

Investors should exercise extreme caution and thoroughly evaluate the potential for significant dilution from the Series D Convertible Preferred Stock's anti-dilution provisions. Consider waiting until the offering is complete and the market has absorbed the new capital structure and the effects of the 1-for-2,000 reverse stock split before making any investment decisions. The lack of a floor price on the conversion price makes future dilution highly unpredictable.

Financial Highlights

debt To Equity
N/A
revenue
$0
operating Margin
N/A
total Assets
$0
total Debt
$0
net Income
$0
eps
$0
gross Margin
N/A
cash Position
$0
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is First Choice Healthcare Solutions, Inc. offering in its S-1/A filing?

First Choice Healthcare Solutions, Inc. is offering 2,400,000 shares of Series D Convertible Preferred Stock and 2,400,000 Warrants to purchase Series D Preferred Stock in its initial public offering, aiming to raise $12,000,000 before expenses.

What is the assumed price for the Series D Convertible Preferred Stock and Warrants?

The assumed combined public offering price for one share of Offered Preferred Stock and an accompanying Warrant is $5.00. The assumed initial conversion price and exercise price are also $5.00 per share.

How many shares of common stock could be issued from this offering for First Choice Healthcare Solutions?

First Choice Healthcare Solutions is registering a total of 8,124,000 shares of Common Stock, which is a good-faith estimate of shares issuable upon conversion of all Series D Convertible Preferred Stock (including Warrant Preferred Stock) and payment of accrued dividends.

What is the impact of the anti-dilution provisions on First Choice Healthcare Solutions' common stock?

The anti-dilution provisions in the Series D Convertible Preferred Stock require the conversion price to be lowered if FCHS issues future securities at a price below $5.00, which will result in a greater number of common shares being issued upon conversion and a greater dilutive effect on existing shareholders.

What is the proposed reverse stock split for First Choice Healthcare Solutions, Inc.?

First Choice Healthcare Solutions, Inc. has proposed a 1-for-2,000 reverse stock split for its 32,958,288 shares of common stock outstanding as of September 17, 2025, to be effective after the registration statement but prior to NYSE listing.

Will First Choice Healthcare Solutions, Inc. be a 'controlled company' after the offering?

No, after the offering, First Choice Healthcare Solutions, Inc. will not be a 'controlled company' because CEO Lance Friedman's 4 shares of Series A Super Voting Preferred Stock will be cancelled, and no individual or group will own a majority of the voting power.

What are the underwriting costs for First Choice Healthcare Solutions' IPO?

The underwriting discounts and commissions for First Choice Healthcare Solutions' IPO are $0.40 per share and accompanying warrant, totaling $960,000 based on the 2,400,000 units offered.

What is the role of the selling stockholders in this First Choice Healthcare Solutions offering?

Concurrent with the IPO, selling stockholders may offer up to 720,000 shares of common stock, including 51,114 shares from warrant exercises, at a fixed price of $5.00 per share until the shares are listed on a national exchange.

What is the primary risk associated with the Series D Convertible Preferred Stock for FCHS investors?

The primary risk is that there is no floor price on the conversion price for the Series D Convertible Preferred Stock, meaning FCHS cannot determine the total number of shares issuable upon conversion, potentially leading to unpredictable and substantial dilution for common shareholders.

Where are First Choice Healthcare Solutions' principal executive offices located?

First Choice Healthcare Solutions, Inc.'s principal executive offices are located at 95 Bulldog Blvd, Suite 202, Melbourne, Florida 32901-1932, with a telephone number of (321) 725-0090.

Risk Factors

Industry Context

First Choice Healthcare Solutions is pivoting to develop a national chain of primary care and wellness clinics, focusing on anti-aging, weight management, and hormone replacement services, alongside pharmacy services. This sector is characterized by increasing demand for personalized health and wellness solutions, but also faces intense competition from established healthcare providers and emerging direct-to-consumer models.

Regulatory Implications

The company's shift to primary care and wellness clinics may subject it to a different set of healthcare regulations, including those related to patient privacy (HIPAA), licensing, and potentially state-specific telehealth regulations. Compliance with these evolving regulations will be critical for operational success.

What Investors Should Do

  1. Scrutinize the business model pivot strategy
  2. Analyze the impact of anti-dilution provisions
  3. Evaluate the effect of the reverse stock split
  4. Monitor cash burn and capital needs post-offering

Key Dates

Glossary

Series D Convertible Preferred Stock
A class of preferred stock that can be converted into a fixed number of common stock shares. It often carries specific rights and preferences over common stock. (This is the primary security being offered in the IPO, with the potential to convert into common stock and dilute existing shareholders.)
Warrants
A security that gives the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (exercise price) within a specified timeframe. (These are offered alongside the preferred stock, providing an additional potential source of capital for the company and further dilution for common stockholders upon exercise.)
Anti-dilution provision
A clause in a security agreement that protects investors from dilution by adjusting the conversion price of their shares if the company issues new shares at a lower price. (This provision in the Series D Preferred Stock poses a significant risk of future dilution for common stockholders.)
Reverse stock split
A corporate action where a company reduces the total number of its outstanding shares by consolidating them. This increases the per-share price. (The company is implementing a 1-for-2,000 reverse stock split, which will drastically reduce the number of outstanding common shares.)
Controlled company
A company where more than 50% of the voting power is held by an individual, a group of individuals acting together, or another company. (The cancellation of CEO Lance Friedman's Series A Super Voting Preferred Stock is intended to prevent FCHS from being classified as a 'controlled company' post-offering.)

Year-Over-Year Comparison

This S-1/A filing represents a significant strategic shift for First Choice Healthcare Solutions, Inc., detailing a pivot away from its legacy orthopedic business towards primary care and wellness clinics. Key metrics from prior filings are not directly comparable due to this fundamental business model change and the proposed capital raise structure involving preferred stock and warrants. New risks related to the business pivot and anti-dilution provisions are prominently featured.

Filing Stats: 4,655 words · 19 min read · ~16 pages · Grade level 17.7 · Accepted 2025-09-23 18:10:11

Key Financial Figures

Filing Documents

Underwriting

Underwriting discounts and commissions (3) $ 0.40 $ 960,000 Proceeds to us (before expenses) $ 4.60 $ 11,040,000 (1) The per share price represents the combined public offering price for one share of Offered Preferred Stock and a Warrant to purchase one share of common stock. The price of a share of the Offered Preferred Stock and accompanying Warrant in this prospectus assumes a combined public offering price of $5 per share and accompanying Warrant and a conversion price and exercise price per share of the Offered Preferred Stock and per Warrant of $5 per share, as the case may be. (2) Assumes no exercise of the over-allotment option to purchase units we have granted to the underwriters as described below. See "Underwriting" on page 73 for a description of total compensation payable to the underwriters. (3) Does not include a reasonable and accountable out-of-pocket expenses not exceeding $75,000 payable to RBW Capital Partners LLC acting through Dawson James Securities, Inc. (the "Representative"), the representative of the underwriters. See "Underwriting" on page 73 for a description of compensation payable to the underwriters. We have granted the underwriters a 45-day option to purchase from us, at the public offering price, less the underwriting discounts, up to 360,000 additional shares of Offered Preferred Stock and/or Warrants to purchase up to 360,000 shares of Warrant Preferred Stock, solely to cover over-allotments, if any. This offering also relates to the additional shares of Offered Preferred Stock and Warrants to purchase shares of Warrant Preferred Stock, issuable upon exercise of the over-allotment option, if any, the common shares issuable upon the exercise of such Offered Preferred Stock and such Warrant Preferred Stock and the shares of common stock issuable upon payment of any dividends accrued on such Offered Preferred Stock and such Warrant Preferred Stock. Unless otherwise noted, the share and per share information in this

DILUTION

DILUTION 32 DESCRIPTION OF CAPITAL STOCK 33 MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 36

BUSINESS

BUSINESS 47 MANAGEMENT 62 EXECUTIVE COMPENSATION 64 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 65 SECURITY 65 SHARES ELIGIBLE FOR FUTURE SALE 66 MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS 68

UNDERWRITING

UNDERWRITING 73 DETERMINATION OF OFFERING PRICE 75 INTERESTS OF NAMED EXPERTS AND COUNSEL 75 EXPERTS 75 LEGAL MATTERS 76 WHERE YOU CAN FIND ADDITIONAL INFORMATION 76 INDEX TO FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS The registration statement of which this prospectus forms a part that we filed with the Securities and Exchange Commission (the "SEC") includes exhibits that provide more detail of the matters discussed in this prospectus. You should read this prospectus and the related exhibits filed with the SEC, together with the additional information described under the headings "Where You Can Find Additional Information" before making your investment decision. You should rely only on the information provided in this prospectus, in any prospectus supplement or in a related free writing prospectus, or documents to which we otherwise refer you. In addition, this prospectus contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. This prospectus includes important information about us, the securities being offered and other information you should know before investing in our securities. You should not assume that the information contained in or incorporated by reference this prospectus is accurate on any date subsequent to the date set forth on the front cover of this prospectus, even though this prospectus is delivered or securities are sold or otherwise disposed of on a later date. It is important for you to read and consider all information contained or incorporated by reference in this prospectus in making your investment decision. All of the summaries in this prospectus are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and

Business

Business Overview First Choice Healthcare Solutions, Inc. ("FCHS," "the Company," "we," "our" or "us") is actively engaged in pivoting the Company's strategy away from our historic orthopedic business model to a strategy of developing a national chain of innovative primary care and wellness clinics focused on providing life improvement services (anti-aging, weight management, and hormone replacement) and pharmacy services, in key high growth markets throughout the U.S. Although we still provide rehabilitative services on a limited basis, such as Physical Therapy, concurrent with the completion of this offering we will terminate all of our remaining legacy orthopedic and Physical Therapy services and focus the company resources on our strategy of building and operating primary care and wellness clinics. Operating Subsidiaries We have operated as First Choice Healthcare Solutions, Inc., a Delaware corpora

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing